ServiceTitanの空売り状況は、投資家がServiceTitanの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

ServiceTitan (NASDAQ:TTAN) 株価情報, 空売り情報

ServiceTitan

ServiceTitan Inc is an end-to-end technology platform built for contractors to transform the performance of their businesses. The Company's platform provides business owners, technicians, customer service representatives and other key office staff with technology tools designed to help customers grow revenue, drive operational efficiencies, deliver a superior end-customer experience and monitor key business drivers in real-time.

ServiceTitan, Inc. - Class A Common Stock

ServiceTitan Inc

WIIM

IVVD

Invivyd shares are trading lower after the company announced the FDA has declined its request to expand its existing emergency use authorization of PEMGARDA.

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $64 price target.

News

Price Target

Reiteration

Analyst Ratings

RYTM

Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $64 Price Target

As of Feb. 24, 2025, three stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Kingsoft Cloud Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>)</h3>
<ul>
<li>On Nov. 19, 2024, Kingsoft Cloud reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million. The company's stock gained around 117% over the past month and has a <a href="https://www.benzinga.com/quote/KC">52-week high of $22.26</a>.</li>
<li>RSI Value: 70.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>KC Price Action: Shares of Kingsoft Cloud gained 2.5% to close at $20.67 on Friday.</li>
</ul>
<h3 class="wp-block-heading">VNET Group Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)</h3>
<ul>
<li>On Nov. 20, VNET Group reported third-quarter EPS and revenue that rose year-over-year. &#8220;We achieved strong third quarter results mainly driven by our wholesale IDC business,&#8221; said Josh Sheng Chen, Founder, Executive Chairperson and interim Chief Executive Officer of VNET. The company's stock gained around 113% over the past month and <a href="https://www.benzinga.com/quote/VNET">has a 52-week high</a> of $16.13.</li>
<li>RSI Value: 89</li>
<li>VNET Price Action: Shares of VNET Group fell 0.6% to close at $14.59 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>)</h3>
<ul>
<li>On Feb. 21, Pony AI launched paid robotaxi services connecting Guangzhou's city center with Baiyun International Airport and South Railway Station. The company said it is the first and only approved to operate on these high-demand routes. The company's stock gained around 77% over the past month and has a <a href="https://www.benzinga.com/quote/PONY">52-week high</a> of $23.88.</li>
<li>RSI Value: 79.8</li>
<li>PONY Price Action: Shares of Pony AI gained 32.1% to close at $23.61 on Friday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month">Top 2 Health Care Stocks That May Rocket Higher This Month</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

PONY

VNET

Top 3 Tech Stocks That May Crash In Q1

ATCH

AtlasClear shares are trading higher. The company reported Q2 financial results.

Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) ("HUSA" or the "Company") today announced that it has entered into a definitive agreement to acquire Abundia Global Impact Group, LLC ("AGIG"), a company specializing in converting waste into high value fuels and chemicals. The acquisition supports HUSA's strategy to diversify its portfolio, expand its global footprint and execute its comprehensive strategy aimed at driving shareholder value through innovation in the renewable energy sector. The agreement is subject to HUSA shareholder approval and standard closing conditions.
Under the terms of the agreement, HUSA will acquire 100% of AGIG's issued and outstanding units from AGIG's members and HUSA will issue to AGIG's members a number of shares of HUSA common stock which shall equal 94% of HUSA's aggregate issued and outstanding common stock at the time of the Closing. AGIG is preparing to build its first advanced plastic recycling facility in Cedar Port, Texas. The facility represents the first phase of a structured, capital-efficient growth plan aimed at scaling and deploying AGIG's suite of technologies for producing renewable fuels and chemicals from waste.

HUSA

Houston American Energy to Acquire Abundia Global, Expands Into Renewable Fuels

Needham analyst Bernie McTernan reiterates Fiverr Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) with a Buy and maintains $36 price target.

FVRR

Needham Reiterates Buy on Fiverr Intl, Maintains $36 Price Target

D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and maintains $21 price target.

TRVI

D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target

As foreshadowed in a January 2025 press release, Connexa Sports Technologies Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) is pleased to announce that its majority-owned subsidiary, Yuanyu Enterprise Management Limited (YYEM), has signed an MCN (Multi-Channel Network) agency services agreement to create and sell content to TikTok as part of its exciting new vertical centered on social networking applications.
Under this agreement, YYEM will procure the production of content to be live-streamed or served as videos to TikTok's multitude of users in the Middle East and North Africa (MENA). This is expected to include engaging broadcasts across various categories, such as sports, gaming, and lifestyle topics, produced by popular Twitch hosts and other influencers within the network that YYEM is developing. We anticipate that YYEM's new vertical will also include live-streaming, voice chat rooms, gaming, and influencer-driven user-generated content (UGC). The fees generated by the arrangement with TikTok will depend on the rate of conversion by TikTok end-users.
With TikTok facing uncertainty in North America, YYEM is aiming to capitalize on the platform's massive reach in the MENA region. As of July 2024, countries like the United Arab Emirates and Saudi Arabia reported TikTok penetration rates exceeding 120% of the adult population, making this a prime market for YYAI and YYEM to target with our new venture.

Connexa Sports Technologies Inc. - Common Stock

YYAI

Connexa Sports' Subsidiary Signs MCN Deal to Create Content for TikTok in MENA

Clear Channel Outdoor shares are trading lower following a Q4 revenue miss and a year-over-year decrease in Q4 EPS results. Additionally, the company issued FY25 and Q1 revenue guidance below estimates.

Stephens &amp; Co. analyst Jim Salera reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Equal-Weight and maintains $420 price target.

Stephens & Co. Reiterates Equal-Weight on Domino's Pizza, Maintains $420 Price Target

April 3, 2025, Logility's Vision25 will bring together top thought leaders, economists, and AI experts for a virtual event featuring keynote insights and interactive boardroom discussions. During each session, senior supply chain executives—including VPs, SVPs, and C-suite leaders—will explore how AI, geopolitical shifts, and evolving market dynamics are reshaping supply chains.
"The supply chain industry is at a turning point," said Allan Dow, President and CEO, Logility.&nbsp; "AI, economic shifts, and geopolitical tensions are pushing leaders to rethink their strategies. Logility's Vision25 is designed to provide the clarity and direction they need to make informed, forward-thinking decisions."
The series opens with Zack Kass, a futurist and former Head of GTM at OpenAI, who will discuss how artificial intelligence is fundamentally changing business operations and decision-making. Other featured speakers include Mark Blyth, Renowned Political Economist &amp; Professor at Brown University, who will explore how to navigate tariff and trade disruptions and turn them into opportunities, while Maria Villablanca, CEO of Future Insights Network, will share insights on how organizations can build resilience and agility in today's volatile global economy.
Joining these thought leaders, Allan Dow, Logility President and CEO, will highlight how companies can turn supply chain challenges into competitive advantages.
Each week, Logility's Vision25 will focus on a key topic affecting supply chain leaders:
<ul>
<li>March 6, 2025: Explore how organizations can thrive through AI&nbsp; transformations and new leadership approaches required for supply chain development.</li>
<li>March&nbsp; 13, 2025: Address tariffs and trade by analyzing global trade movements and make the most of resulting opportunities.</li>
<li>March 20, 2025: Learn how GenAI can transform supply chain resilience through AI-powered solutions.</li>
<li>March 27, 2025: Discover benchmarks for strategic decision-making in uncertain environments.</li>
<li>April 3, 2025: Logility's Inaugural Reimagine Client Awards will honor innovation and excellence in supply chain transformation.</li>
</ul>
Beyond thought leadership, Logility's Vision25 offers real-world strategies and actionable insights. Attendees will gain exclusive access to Logility's Supply Chain Horizons 2025 Market Report, which highlights emerging trends and key data shaping the industry.

LGTY

Logility's Vision25 to Explore AI, Trade, and Market Shifts Impacting Global Supply Chains

Ukraine and the United States are approaching a deal regarding Ukraine's rare earth minerals, but President Volodymyr Zelensky remains committed to security guarantees. His administration <a target="_blank" href="https://www.benzinga.com/markets/commodities/25/02/43788546/ukraine-officials-stall-trumps-colonial-rare-earths-bid-prefer-mutually-beneficial-deal" rel="noreferrer noopener">delayed the initial push</a> to sign the agreement, asking for military assurances and disputing the financials.
"I don't want something that 10 generations of Ukrainians will have to pay back," Zelensky said at Sunday's press conference, according <a target="_blank" href="https://www.wsj.com/world/ukraines-zelensky-wants-better-terms-on-minerals-deal-demanded-by-trump-7d3a092f" rel="noreferrer noopener">to</a> the Wall Street Journal.
The minerals deal is a part of President Donald Trump's effort to broker a ceasefire on the three-year conflict, as gaining access to Ukraine's resources would reduce reliance on foreign supply chains.
Still, Ukraine is absent from direct negotiations between Washington and Moscow in Saudi Arabia, raising concerns about Kyiv being sidelined from discussions about its own future.
Zelensky warned that Ukraine would not agree to the deal if it did not serve the country's long-term interests. "The deal must be ‘win-win' for Ukraine and the U.S.," he said, pushing back against the Trump administration's argument that American business investments in Ukraine alone would be a security guarantee.
The friction between Kyiv and Washington has risen, with the NY Times <a target="_blank" href="https://www.nytimes.com/2025/02/19/world/europe/ukraine-zelensky-trump-russia-war.html" rel="noreferrer noopener">reporting</a> that Trump called Zelensky a "dictator "for postponing the elections while Zelensky accused Trump of spreading Russian disinformation. Regardless of those tensions, both administrations have proceeded with "constructive "negotiations, per Ukraine's chief of staff, Andrii Yermak.
Despite Trump's interests, it is worth mentioning Ukraine has no internationally recognized rare earth reserves. The country commercially produces some critical minerals, like titanium and gallium, but not at a scale comparable to the enormous sums Trump has suggested.
Ukraine's geological agencies have estimated notable potential deposits, but they are largely undeveloped. Bringing mines into production is a notoriously <a target="_blank" href="https://www.benzinga.com/news/24/07/39870803/us-mine-development-delays-among-worlds-longest-second-only-to-zambia" rel="noreferrer noopener">slow and costly process</a>.
Zelensky also pointed out the disparity between U.S. claims about the cost of its support. While Trump has referenced figures as high as $500 billion, Ukraine's estimates place total U.S. assistance closer to $120 billion, according to the <a target="_blank" href="https://www.ifw-kiel.de/topics/war-against-ukraine/ukraine-support-tracker/" rel="noreferrer noopener">Kiel Institute</a>.
"The question of $500 billion is no longer there," Zelensky said, referring to the initial demand from Washington. "We do not recognize the debt," he added, clarifying that Ukraine would not accept an arrangement that treats U.S. aid as a loan to be repaid through mineral revenues.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/25/02/43900287/trumps-10-oil-tariff-could-deal-10-billion-annual-blow-to-canada-and-other-foreign-producers-goldman-sachs-warns" target="_blank" rel="noreferrer noopener">Trump's 10% Oil Tariff Could Deal $10 Billion Annual Blow To Canada And Other Foreign Producers, Goldman Sachs Warns</a></li>
</ul>
Image via Shutterstock

Government

Commodities

Politics

Legal

Global

Zelensky Says Ukraine Won't Trade Minerals For Debt, Seeks 'Win-Win' Deal With US

Goldman Sachs analyst Leah Jordan downgrades Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from Buy to Neutral and lowers the price target from $33 to $26.

Downgrades

Goldman Sachs Downgrades Conagra Brands to Neutral, Lowers Price Target to $26

TRDA

Entrada Therapeutics shares are trading higher after the company announced that the FDA removed the clinical hold on ENTR-601-44 and that it has obtained clearance status.

TD Securities analyst Andrew Charles reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Buy and maintains $490 price target.

TD Securities Reiterates Buy on Domino's Pizza, Maintains $490 Price Target

Global life and health reinsurance entity Reinsurance Group of America, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Monday.
The company has reached an agreement with Equitable Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) to reinsure a wide <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43907362/rga-announces-reinsurance-transaction-with-equitable-holdings" rel="noreferrer noopener">range of life insurance products</a>.
Under the terms of the deal, RGA is reinsuring&nbsp;75%&nbsp;of Equitable&#8217;s in-force life insurance liabilities. The block includes approximately&nbsp;$18 billion&nbsp;of general account reserves and&nbsp;$14 billion&nbsp;of separate account reserves.
This deal is set up to allow RGA to invest $1.5 billion in capital at the closing. It is expected to generate returns within RGA&#8217;s projected range, while also providing a notable increase in the company&#8217;s adjusted operating earnings per share.
Furthermore, the agreement expands RGA&#8217;s partnership with Equitable across various sectors, including underwriting, product creation, distribution, and investment management.
&#8220;This partnership is an example of our capacity to provide creative solutions and technical expertise that support both sides of the balance sheet, and it is a prime example of how the execution of our Creation Re strategy can address our clients&#8217; current and future needs,&#8221; said Executive Vice President, Head of the Americas, RGA, Ron Herrmann.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success" rel="noreferrer noopener">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a>
The deal is expected to contribute around $70 million to adjusted operating income before taxes in 2025. This amount is anticipated to increase to between $160 million and $170 million in 2026, eventually stabilizing at around $200 million each year thereafter.
&#8220;Our strong financial position enables us to capitalize on this opportunity with Equitable, and the transaction is expected to meaningfully contribute to RGA&#8217;s earnings per share, with anticipated attractive returns on capital,&#8221; said Executive Vice President, Chief Financial Officer, RGA, Axel André.
RGA intends to fund the transaction with surplus capital and, if necessary, proceeds from debt financing, contingent on market conditions. The transaction is set to close in mid-2025, pending regulatory approval and other customary closing conditions.
The deal is expected to create more than $2 billion in value for Equitable Holdings, encompassing a favorable ceding <a target="_blank" href="https://www.benzinga.com//node/43907593" rel="noreferrer noopener">commission and the release of capital.</a>
Also, Equitable plans to execute $500 million of incremental share repurchases, above the company&#8217;s 60-70% payout ratio target, following the close of the transaction.
Additionally, Equitable announced its intention to <a target="_blank" href="https://www.benzinga.com//node/43907646" rel="noreferrer noopener">increase its ownership stake in AB</a> through a tender offer to purchase up to $1.8 billion of units of AllianceBernstein Holding L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>)
Price Action: RGA shares are trading higher by 3.55% at $196.11 in premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43887830/openai-expands-operator-ai-agent-to-multiple-countries" target="_blank" rel="noreferrer noopener">OpenAI Expands Operator AI Agent To Multiple Countries</a></li>
</ul>
Photo via Shutterstock.

Equities

Asset Sales

General

Equitable Inks Reinsurance Deal With RGA And Plans To Boost Stake In AllianceBernstein: Details

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The formation of OSDC coincides with formal strategic options initiatives to create value from the Company's leading-edge, patented silicone dioxide-based, pH sensitive tunable antibody drug conjugates (tADC) &amp; other tunable drug conjugates (tDC) platforms. The Company has initiated discussions with clinical-stage ADC therapeutics companies in the U.S., China and other jurisdictions to form joint ventures (JVs) pairing those companies' clinical-stage assets with certain assets from the tADC and/or tDC platforms and spinning the JVs into standalone public companies. If successful, OS Therapies intends to provide stock dividends of the public JVs to shareholders.
The OST-tADC and OST-tDC technologies are centered around the Company's proprietary next-generation tunable Antibody Drug Conjugate (tADC) and tunable Drug Conjugates (tDC) platforms. These advanced technologies incorporate pH-sensitive silicon-based linkers: SiLinkers&#x2122; to link the targeting antibodies (or antibody fragments) and therapeutic moieties together while coating the entire package with pH sensitive coating. This strategy can release multiple therapeutic agents selectively within the tumor and tumor microenvironment, which have lower pH levels than the rest of the body. This approach aims to maximize the therapeutic effects while minimizing damage to healthy cells.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bccresearch.com%2Fmarket-research%2Fpharmaceuticals%2Fantibody-drug-conjugates-markets-report.html%3Fsrsltid%3DAfmBOoqRPnbxc1SPE0lx3HkAmQ-I2X4xd3bWqvtaZu1wAT7gR0oCGUkb&amp;esheet=54212694&amp;newsitemid=20250224482242&amp;lan=en-US&amp;anchor=BCC+Research&amp;index=1&amp;md5=dda6f15610fa07a596439cc152c306cc">BCC Research</a> estimates that the global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.

Dividends

OSTX

OS Therapies Launches Subsidiary to Advance Tunable Antibody Drug Conjugates, Plans Stock Dividends for Shareholders

Goldman Sachs analyst Leah Jordan initiates coverage on Smithfield Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFD#NASDAQ">SFD</a>) with a Buy rating and announces Price Target of $32.

Initiation

Goldman Sachs Initiates Coverage On Smithfield Foods with Buy Rating, Announces Price Target of $32

Barclays analyst David Anderson maintains Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) with a Overweight and raises the price target from $48 to $50.

Barclays Maintains Overweight on Tenaris, Raises Price Target to $50

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy and maintains $9 price target.

Comments

ServiceTitan

空売り

ServiceTitan (NASDAQ:TTAN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル